Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | TP53 Y220C TP53 R248W |
| Therapy | Rezatapopt |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TP53 Y220C TP53 R248W | Advanced Solid Tumor | resistant | Rezatapopt | Preclinical - Cell culture | Actionable | In a preclinical study, cancer cell lines expressing TP53 Y220C and R248W were resistant to Rezatapopt (PC14586) treatment in culture (PMID: 41504628). | 41504628 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (41504628) | Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators. | Full reference... |